Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03617263 |
Recruitment Status :
Recruiting
First Posted : August 6, 2018
Last Update Posted : October 10, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-alcoholic Fatty Liver Disease in Women With PCOS | Drug: Saroglitazar Magnesium 4 mg Tablet Drug: Placebo | Phase 2 |
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS. \
The study will be conducted over a period of up to 34 weeks and will include Screening (Days -28 to -7) Phase, a 24-week Treatment Phase following randomization on Day 1.
The primary endpoint of the study is change in hepatic fat content from baseline following 24 weeks of treatment as measured by MRI-PDFF.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Phase 2A, Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating NAFLD in Women With Polycystic Ovary Syndrome (PCOS) |
Actual Study Start Date : | December 4, 2018 |
Estimated Primary Completion Date : | April 2024 |
Estimated Study Completion Date : | July 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Saroglitazar Magnesium 4 mg
Saroglitazar Magnesium once daily in the morning before breakfast
|
Drug: Saroglitazar Magnesium 4 mg Tablet
Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
Other Name: Not any |
Placebo Comparator: Placebo
Placebo tablet once daily in the morning before breakfast
|
Drug: Placebo
Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
Other Name: Not any |
- Hepatic fat content [ Time Frame: 24 weeks ]Change in hepatic fat content from baseline following 24 weeks of treatment as measured by MRI-PDFF
- Liver enzymes/LFTs [ Time Frame: 12 and 24 weeks ]Changes from baseline to week 12 and week 24 in liver enzymes/LFTs: ALT, AST, ALP,GGT, serum protein, albumin and total bilirubin.
- Insulin resistance [ Time Frame: 12 and 24 weeks ]Changes from baseline to week 12 and week 24 in insulin resistance as measured by HOMA
- Markers of liver injury [ Time Frame: 24 weeks ]Changes from baseline to week 24 in markers of liver injury
- Liver fibrosis [ Time Frame: 24 weeks ]Changes from baseline to week 24 in fibrosis including CK-18, hs-CRP, and TNFα
- Liver stiffness [ Time Frame: 24 weeks ]Changes from baseline to week 24 in liver stiffness measured by transient elastography/FibroScan
- Controlled attenuation parameter [ Time Frame: 24 weeks ]Changes from baseline to week 24 in controlled attenuation parameter measured by transient elastography/ FibroScan
- BMI [ Time Frame: 12 and 24 weeks ]Changes from baseline to week 12 and week 24 in BMI
- Waist circumference [ Time Frame: 12 and 24 weeks ]Changes from baseline to week 12 and week 24 in waist circumference
- MRI-derived measures of total liver fat index (It will be calculated as the product of liver volume and the liver mean proton-density fat fraction across all liver segments) [ Time Frame: 24 weeks ]Changes from baseline to week 24 in MRI-derived measures of total liver fat index
- MRI-derived measures of total liver volume (Liver volume will be calculated after complete segmentation by summing the liver surface area at each segmented slice, and then multiplying this sum by individual slice thickness, in millilitres [mL]) [ Time Frame: 24 weeks ]Changes from baseline to week 24 in MRI-derived measures of total liver volume
- Lipid and lipoprotein levels [ Time Frame: 12 and 24 weeks ]Changes from baseline to week 12 and week 24 in lipid and lipoprotein levels: TG, TC, HDL, LDL, sdLDL, VLDL, apolipoprotein A and apolipoprotein B
- SHBG level [ Time Frame: 12 and 24 weeks ]Changes from baseline to week 12 and week 24 in SHBG level
- Ovarian function [ Time Frame: 12 and 24 weeks ]Changes from baseline to week 12 and week 24 in ovarian function (Total testosterone, 17-hydroxyprogesterone, free testosterone, luteinizing hormone, follicle-stimulating hormone, LH-to-FSH ratio and estradiol)
- Free androgen index ( Total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by a constant, usually 100. The concentrations of testosterone and SHBG are normally measured in nanomols per liter. [ Time Frame: 12 and 24 weeks ]Changes from baseline to week 12 and week 24 in free androgen index
- Peak Plasma concentration [Cmax] (For Single Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following first dose
- Time to reach peak Plasma concentration [Tmax] (For Single Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following first dose
- Area under Plasma concentration vs. time curve till the last time point [AUC0-t] (For Single Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following first dose
- Area under Plasma concentration vs. time curve extrapolated to the infinity (AUC0-∞) after first dose (For Single Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following first dose
- Area under plasma concentration vs. time curve in a 24 h dosing interval (AUCtau) after first dose (For Single Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following first dose
- Elimination rate constant [Kel] (For Single Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following first dose
- Elimination half-life [tHalf] (For Single Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following first dose
- Apparent Volume of distribution [Vd/F] (For Single Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following first dose
- Apparent Clearance [CL/F] (For Single Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following first dose
- Peak Plasma concentration [Cmax,ss] (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
- Time to reach peak Plasma concentration [Tmax,ss] (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
- Area under plasma concentration vs. time curve in a 24 h dosing interval (AUCtau) after last dose (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
- Elimination rate constant [Kel,ss] (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
- Elimination half-life [thalf,ss] (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
- Apparent Volume of distribution [Vd/F,ss] (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
- Apparent Clearance [CL/F,ss] (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
- Minimal or Trough plasma concentration [Cmin] (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
- Fluctuation index (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
- Accumulation index calculated as a ratio of AUCtau (last dose)/AUCtau (first dose) (For Multiple Dose) [ Time Frame: 24 weeks ]Pharmacokinetics of Saroglitazar following last dose
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Females, 18 to 45 years of age.
-
Previously confirmed diagnosis of PCOS:
- oligo-and/or anovulation;
- hyperandrogenism (clinical and/or biochemical);
- polycystic ovary morphology on ultrasonography
- Evidence of NAFLD within 6 months prior to the Screening Visit (Visit 1).
- Alanine transaminase ≥ 38 U/L at Visit 1. Visit 2 ALT must not increase >30% from Visit 1.
- Hepatic fat fraction ≥10% by MRI-PDFF.
- Willingness to participate in the study.
- Ability to understand and give informed consent for participation.
- Woman who agrees to use the contraceptive methods.
Exclusion Criteria:
- Presence of other chronic liver diseases (hepatitis B or C, autoimmune hepatitis, cholestatic liver disease, Wilsons disease, hemochromatosis, etc.).
- Average alcohol consumption ≥ 7 drinks per week for women in the 6 months prior to enrollment.
- Clinical, imaging, or histological evidence of cirrhosis.
- Patients who have used medications known to cause hepatic steatosis for more than 2 weeks in the past year.
- Prior bariatric surgery.
- Weight loss of more than 5% in the 3 months preceding screening.
- Severe co-morbidities (e.g., advanced cardiac, renal, pulmonary, or psychiatric illness).
- Known allergy, sensitivity or intolerance to Saroglitazar Magnesium, comparator or formulation ingredients.
- Use of antidiabetic and lipid lowering medications if the dose is not stable for at least the 3 months preceding screening.
- Intake of Vitamin E (>100 IU/day) or multivitamins containing Vitamin E (>100 IU/day) 3 months before enrollment.
- Use of drugs with potential effect on NAFLD/NASH in the 3 months prior to screening.
- Illicit substance abuse within the past 12 months.
- Pregnant or breast feeding females.
- Women with known Cushing syndrome or hyperprolactinemia.
- Refusal or inability to comply with the requirements of the protocol, for any reason, including scheduled clinic visits and laboratory tests.
- History of myopathies or evidence of active muscle diseases.
- History or current significant cardiovascular disease.
- History of malignancy.
- History of bladder disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03617263
Contact: Farheen Shaikh | +1 6094534751 | fshaikh@zydustherapeutics.com |
United States, Arizona | |
Dr.Anita Kohli | Recruiting |
Chandler, Arizona, United States, 85224 | |
Contact: Mari Johnson johnsonmari87@gmail.com | |
United States, California | |
Dr.Robert Allen Jenders | Recruiting |
Panorama City, California, United States, 91402 | |
Contact: Vanessa Delgado 818-532-6880 ext 3109 vanessa.delgado@nritrials.com | |
University of California, San Francisco | Recruiting |
San Francisco, California, United States, 94143 | |
Contact: Yanin T Srisengfa 415-502-3725 yanin.srisengfa@ucsf.edu | |
Contact: Rayshawnda Davis 415-502-3725 rayshawnda.davis@ucsf.edu | |
Principal Investigator: Dr. Monika Sarkar | |
United States, Colorado | |
Dr.Melanie Cree Green | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Wesley Pendleton, MS, RDN 720-777-5974 Wesley.Pendleton@childrenscolorado.org | |
Contact: Nicola Haakonsen NICOLA.HAAKONSEN@CUANSCHUTZ.EDU | |
United States, Florida | |
Dr. Yaneicy Gonzalez Rojas | Recruiting |
Miami, Florida, United States, 33125 | |
Contact: Laylien Souza 305-702-0024 souza@optimusu.com | |
United States, Indiana | |
Indiana University Health | Recruiting |
Indianapolis, Indiana, United States, 46202 | |
Contact: Regina Weber 317-278-6266 reginaw@iu.edu | |
Principal Investigator: Dr. Niharika Samala | |
United States, North Carolina | |
Dr. KATHRYN JEAN LUCAS | Recruiting |
Morehead City, North Carolina, United States, 28557 | |
Contact: Ashley Bissette, BSC ashley.bissette@lucasresearch.org | |
United States, Texas | |
Dr. Nicole Loo | Recruiting |
San Antonio, Texas, United States, 78215 | |
Contact: Bertha Buan 210-253-3426 bbuan@txliver.com | |
Dr. Mark Kipnes | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: Josette Negrete 210-614-8612 ext 1515 josette.negrete@dgdclinic.com | |
Mexico | |
Centro de Investigación Medico Biológica y Terapia Avanzada SC (CIMBYTA) | Active, not recruiting |
Guadalajara, Jalisco, Mexico, 44130 | |
Hospital Universitario "Dr. Jose Eleuterio Gonzalez" | Active, not recruiting |
Monterrey, Nuevo León, Mexico, 64460 | |
UBAM Unidad Biomédica Avanzada Monterrey | Active, not recruiting |
Monterrey, Nuevo León, Mexico, 64460 | |
Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada S.C. | Active, not recruiting |
Culiacán, Sinaloa, Mexico, 80230 | |
Medical Care and Research S.A. de C.V. | Active, not recruiting |
Mérida, Yucatán, Mexico, 97070 | |
CEMDEC S.A. de C.V. (Centero Mexicana Desarrollo de Estudios Clinicos) | Active, not recruiting |
Ciudad de mexico, Mexico, 06100 |
Study Director: | Deven Parmar, MD | Zydus Therapeutics Inc. |
Responsible Party: | Zydus Therapeutics Inc. |
ClinicalTrials.gov Identifier: | NCT03617263 |
Other Study ID Numbers: |
SARO.17.009 |
First Posted: | August 6, 2018 Key Record Dates |
Last Update Posted: | October 10, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
NAFLD PCOS Saroglitazar Magnesium |
Liver Diseases Fatty Liver Non-alcoholic Fatty Liver Disease Digestive System Diseases |